GSK's main partner in the consumer health joint venture that became Haleon – Pfizer – holds the remaining 32% in the new company and has said that it will sell its stake now that the ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

Both GSK and Pfizer have been selling their holdings in Haleon at a fair clip. This month, Pfizer reduced its holding by 640m shares, selling them for ~$5.1 each for a total value of ~$2.43bn.

Haleon backed its full-year guidance despite ... healthcare business—which was spun out of GSK and is partly owned by Pfizer—said Thursday that revenue for the quarter was 2.78 billion pounds ...

During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of its shares of Haleon, a consumer health joint venture with GSK. In Pfizer's Q3 earnings call ...

Bank of America Securities analyst Victoria Petrova has maintained their bullish stance on HLN stock, giving a Buy rating on November 4.

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...